192 related articles for article (PubMed ID: 16537704)
1. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.
Orr-Urtreger A; Bar-Shira A; Bercovich D; Matarasso N; Rozovsky U; Rosner S; Soloviov S; Rennert G; Kadouri L; Hubert A; Rennert H; Matzkin H
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):474-9. PubMed ID: 16537704
[TBL] [Abstract][Full Text] [Related]
2. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
3. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
4. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel.
Figer A; Irmin L; Geva R; Flex D; Sulkes J; Sulkes A; Friedman E
Br J Cancer; 2001 Feb; 84(4):478-81. PubMed ID: 11207041
[TBL] [Abstract][Full Text] [Related]
5. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
Rennert H; Bercovich D; Hubert A; Abeliovich D; Rozovsky U; Bar-Shira A; Soloviov S; Schreiber L; Matzkin H; Rennert G; Kadouri L; Peretz T; Yaron Y; Orr-Urtreger A
Am J Hum Genet; 2002 Oct; 71(4):981-4. PubMed ID: 12145743
[TBL] [Abstract][Full Text] [Related]
6. The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel.
Dagan E; Laitman Y; Levanon N; Feuer A; Sidi AA; Baniel J; Korach Y; Ben Baruch G; Friedman E; Gershoni-Baruch R
Fam Cancer; 2006; 5(4):389-95. PubMed ID: 16944274
[TBL] [Abstract][Full Text] [Related]
7. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
8. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.
Drucker L; Stackievitz R; Shpitz B; Yarkoni S
Anticancer Res; 2000; 20(1B):559-61. PubMed ID: 10769725
[TBL] [Abstract][Full Text] [Related]
9. Genetic analyses in consecutive israeli jewish colorectal cancer patients.
Fidder HH; Figer A; Geva R; Flex D; Schayek H; Avidan B; Meir SB; Friedman E
Am J Gastroenterol; 2005 Jun; 100(6):1376-80. PubMed ID: 15929773
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
Nupponen NN; Wallén MJ; Ponciano D; Robbins CM; Tammela TL; Vessella RL; Carpten JD; Visakorpi T
Genes Chromosomes Cancer; 2004 Feb; 39(2):119-25. PubMed ID: 14695991
[TBL] [Abstract][Full Text] [Related]
11. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer.
Hebbring SJ; Fredriksson H; White KA; Maier C; Ewing C; McDonnell SK; Jacobsen SJ; Cerhan J; Schaid DJ; Ikonen T; Autio V; Tammela TL; Herkommer K; Paiss T; Vogel W; Gielzak M; Sauvageot J; Schleutker J; Cooney KA; Isaacs W; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):935-8. PubMed ID: 16702373
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 mutations and prostate cancer in Poland.
Cybulski C; Górski B; Gronwald J; Huzarski T; Byrski T; Debniak T; Jakubowska A; Wokołorczyk D; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Romuald Z; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Posmyk M; Narod SA; Lubiński J
Eur J Cancer Prev; 2008 Feb; 17(1):62-6. PubMed ID: 18090912
[TBL] [Abstract][Full Text] [Related]
13. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
[TBL] [Abstract][Full Text] [Related]
14. Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?
Bar-Sade RB; Theodor L; Gak E; Kruglikova A; Hirsch-Yechezkel G; Modan B; Kuperstein G; Seligsohn U; Rechavi G; Friedman E
Eur J Hum Genet; 1997; 5(6):413-6. PubMed ID: 9450187
[TBL] [Abstract][Full Text] [Related]
15. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.
Sun J; Wiklund F; Hsu FC; Bälter K; Zheng SL; Johansson JE; Chang B; Liu W; Li T; Turner AR; Li L; Li G; Adami HO; Isaacs WB; Xu J; Grönberg H
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):480-5. PubMed ID: 16537705
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
[TBL] [Abstract][Full Text] [Related]
17. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
Horsburgh S; Matthew A; Bristow R; Trachtenberg J
Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
[TBL] [Abstract][Full Text] [Related]
18. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
